País: Canadá
Língua: inglês
Origem: Health Canada
SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE)
APOTEX INC
A10BH03
SAXAGLIPTIN
5MG
TABLET
SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) 5MG
ORAL
15G/50G
Prescription
DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS
Active ingredient group (AIG) number: 0152653001; AHFS:
APPROVED
2021-03-08
Page 1 of 43 PRODUCT MONOGRAPH PR APO-SAXAGLIPTIN Saxagliptin Tablets 2.5 mg and 5 mg saxagliptin (as saxagliptin hydrochloride) Oral Antihyperglycemic Agent DPP-4 inhibitor Incretin Enhancer APOTEX INC. Date of Revision: 150 Signet Drive, December 30, 2021 Toronto, Ontario, M9L 1T9 Submission Control No: 253039 Page 2 of 43 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 3 SUMMARY PRODUCT INFORMATION ...................................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................................... 3 CONTRAINDICATIONS ............................................................................................................. 4 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS.............................................................................................................. 7 DRUG INTERACTIONS .............................................................................................................16 DOSAGE AND ADMINISTRATION............................................................................................20 OVERDOSAGE .........................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY.............................................................................21 STORAGE AND STABILITY ......................................................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING................................................................24 PART II: SCIENTIFIC INFORMATION ....................................................................................26 PHARMACEUTICAL INFORMATION ........................................................................................26 CLINICA Leia o documento completo